vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP (NEN). Click either name above to swap in a different company.
NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP is the larger business by last-quarter revenue ($23.6M vs $18.7M, roughly 1.3× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -677.3%, a 676.5% gap on every dollar of revenue. On growth, NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP posted the faster year-over-year revenue change (15.7% vs -25.7%). Over the past eight quarters, NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP's revenue compounded faster (8.9% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
New England Realty Associates Limited Partnership is a real estate investment entity that owns, operates and manages residential and commercial properties primarily across the U.S. New England region. Its core assets include multifamily apartments, mixed-use properties and small commercial spaces, serving tenants across Massachusetts, New Hampshire and adjacent states, delivering steady returns to unitholders via rental income and property value growth.
CTMX vs NEN — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $23.6M |
| Net Profit | $-154.0K | $-1.4M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 14.0% |
| Net Margin | -0.8% | -677.3% |
| Revenue YoY | -25.7% | 15.7% |
| Net Profit YoY | 97.6% | -133.0% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $23.6M | ||
| Q3 25 | — | $23.7M | ||
| Q2 25 | $18.7M | $21.2M | ||
| Q1 25 | $50.9M | $20.7M | ||
| Q4 24 | $38.1M | $20.4M | ||
| Q3 24 | $33.4M | $20.2M | ||
| Q2 24 | $25.1M | $20.1M | ||
| Q1 24 | $41.5M | $19.9M |
| Q4 25 | — | $-1.4M | ||
| Q3 25 | — | $-521.8K | ||
| Q2 25 | $-154.0K | $4.1M | ||
| Q1 25 | $23.5M | $3.8M | ||
| Q4 24 | $18.9M | $4.2M | ||
| Q3 24 | $5.7M | $3.9M | ||
| Q2 24 | $-6.5M | $4.1M | ||
| Q1 24 | $13.8M | $3.5M |
| Q4 25 | — | 14.0% | ||
| Q3 25 | — | 20.0% | ||
| Q2 25 | -6.9% | 33.3% | ||
| Q1 25 | 44.4% | 30.1% | ||
| Q4 24 | 46.4% | 32.4% | ||
| Q3 24 | 12.3% | 32.0% | ||
| Q2 24 | -33.7% | 32.6% | ||
| Q1 24 | 28.1% | 28.9% |
| Q4 25 | — | -677.3% | ||
| Q3 25 | — | -2.2% | ||
| Q2 25 | -0.8% | 19.5% | ||
| Q1 25 | 46.2% | 18.3% | ||
| Q4 24 | 49.6% | 20.7% | ||
| Q3 24 | 17.2% | 19.3% | ||
| Q2 24 | -26.0% | 20.3% | ||
| Q1 24 | 33.3% | 17.4% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $26.7M |
| Total DebtLower is stronger | — | $531.0M |
| Stockholders' EquityBook value | $119.9M | — |
| Total Assets | $175.1M | $505.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.7M | ||
| Q3 25 | — | $13.4M | ||
| Q2 25 | $49.0M | $16.7M | ||
| Q1 25 | $47.6M | $30.9M | ||
| Q4 24 | $38.1M | $17.6M | ||
| Q3 24 | $40.6M | $15.1M | ||
| Q2 24 | $43.2M | $13.5M | ||
| Q1 24 | $36.2M | $28.8M |
| Q4 25 | — | $531.0M | ||
| Q3 25 | — | $514.2M | ||
| Q2 25 | — | $514.3M | ||
| Q1 25 | — | $407.8M | ||
| Q4 24 | — | $408.6M | ||
| Q3 24 | — | $409.3M | ||
| Q2 24 | — | $410.0M | ||
| Q1 24 | — | $410.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $119.9M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | — | ||
| Q2 24 | $-31.2M | — | ||
| Q1 24 | $-31.7M | — |
| Q4 25 | — | $505.3M | ||
| Q3 25 | — | $492.9M | ||
| Q2 25 | $175.1M | $494.8M | ||
| Q1 25 | $98.5M | $385.2M | ||
| Q4 24 | $120.5M | $393.5M | ||
| Q3 24 | $139.0M | $387.4M | ||
| Q2 24 | $159.2M | $383.7M | ||
| Q1 24 | $184.7M | $381.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $27.7M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.7M | ||
| Q3 25 | — | $2.3M | ||
| Q2 25 | $-15.8M | $12.5M | ||
| Q1 25 | $-21.0M | $5.5M | ||
| Q4 24 | $-19.9M | $31.9M | ||
| Q3 24 | $-20.7M | $8.5M | ||
| Q2 24 | $-19.5M | $5.4M | ||
| Q1 24 | $-26.0M | $6.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 3.02× | ||
| Q1 25 | -0.89× | 1.44× | ||
| Q4 24 | -1.05× | 7.57× | ||
| Q3 24 | -3.61× | 2.17× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | -1.89× | 1.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
NEN
Segment breakdown not available.
